Introduction
============

According to the WHO classification, primary clear cell carcinoma of the pancreas is classified as a rare "miscellaneous" carcinoma;[@b1-ott-11-8197] morphologically it is similar to the clear cell carcinoma of renal. It was first described by Cubilla in 1980.[@b2-ott-11-8197] Because only few cases have been reported in the literature, the systematic overview of this tumor entity is insufficient. We report a rare case of primary clear cell carcinoma of the pancreas, review, and update the medical literature reported of this neoplasm.

Case report
===========

A 64-year-old male presented to our hospital with a year history of epigastric pain, radiating to the back, and 6 kg weight loss. He had no history of carcinoma and had a history of laparoscopic cholecystectomy 10 years ago. He had smoked 20 cigarettes per day for 30 years and drank alcohol on occasion. The family history was negative for malignant diseases. Physical examination revealed tenderness over the epigastric area. There were no enlarged superficial lymph nodes nor any palpable mass in the abdomen; the liver and spleen were not enlarged. The laboratory findings were all within the normal ranges except tumor markers. Tumor marker assay showed that serum carcinoembryonic antigen (CEA) was 18.56 ng/mL (normal: 0--5 ng/mL), the serum cancer antigen (CA) 19--9 was 649.15 U/mL (normal: 0--37 U/mL), CA125 was 132.97 U/L (normal: 0--35 kU/L), CA242 was 393.93 U/L (normal: 0--20 kU/L), neuron-specific enolase was 11 ng/mL (normal: 0--25 ng/mL), CYFRA21--1 was 1.7 ng/L (normal: 0--5 ng/L). Abdominal computed tomography (CT) showed a 40 × 45 mm heterogeneous irregular hypodense mass in the distal body and tail of the pancreas ([Figure 1A](#f1-ott-11-8197){ref-type="fig"}), and it was enhanced after infusion of contrast material ([Figure 1B](#f1-ott-11-8197){ref-type="fig"}). Positron emission tomography-CT showed diffuse abnormal uptake only in the pancreatic mass ([Figure 1C](#f1-ott-11-8197){ref-type="fig"}).

Preoperatively, it was diagnosed as an adenocarcinoma of the pancreas. Distal pancreatectomy and splenectomy were performed, and the specimen was sent for histopathological examination ([Figure 2A](#f2-ott-11-8197){ref-type="fig"}). Microscopically, highly atypical glands were composed of round or oval bulky cells with abundant clear cytoplasm and well-defined cell borders ([Figure 2B and C](#f2-ott-11-8197){ref-type="fig"}). These tumor cells were arranged as solid trabeculae, cords, and tubules. The hobnail appearance of cell arrangement was seen in some tumor cells. Nuclei were small, moderately pleomorphic with irregular borders, and often were eccentrically placed. These features were present in more than 90% of the tumor cells. Immunohistochemistry showed strong and diffuse staining for cytokeratin-7 (CK-7) ([Figure 3A](#f3-ott-11-8197){ref-type="fig"}), and the immunohistochemistry staining was negative for chromogranin A (CGA), synaptophysin (SYN), hepatocyte nuclear factor-1β (HNF-1β) ([Figure 3B](#f3-ott-11-8197){ref-type="fig"}), and carbonic anhydrase 9 (CA9) ([Figure 3C](#f3-ott-11-8197){ref-type="fig"}). The patient recovered well and was discharged 10 days after surgery. CT scan revealed multiple hepatic metastasis 3 months after surgery, then he received gemcitabine chemotherapy and died 2 months later.

Discussion
==========

Clear cell carcinoma occurs mostly in the kidney, lung, ovary, and thyroid, but this tumor extremely rarely originates from the pancreas.[@b3-ott-11-8197] This is also the first time we have encountered primary pancreatic clear cell carcinoma, diagnosed by pathology and immunohistochemistry. We summarized our case and the available 12 cases of pancreatic clear cell carcinoma reported previously ([Table 1](#t1-ott-11-8197){ref-type="table"}). The age of the patients (nine males and three females) was 46--75 years, an average age of 64.4 years. The clinical symptoms are not specific, mainly manifested as abdominal pain, radiating to the back, jaundice, anorexia weight loss, and so on. Tumor biomarkers in these patients, such as serum CA19--9, CA125, CA242, CEA, can be elevated or normal. There are no specific diagnostic criteria for it. The diagnosis relies mainly on typical pathological features with abundant clear cytoplasm and prominent cell boundaries. Immunohistochemistry is a complementary method to distinguish from other tumors. Immunohistochemistry almost showed reactions to antibodies against CK-7 in all cases, while showed no reactions to neuroendocrine markers such as CGA, SYN in all cases. Sequencing of the K-ras oncogene was analyzed in three cases,[@b4-ott-11-8197]--[@b6-ott-11-8197] and a mutation at codon 12 in K-ras oncogene was detected in two cases,[@b5-ott-11-8197],[@b6-ott-11-8197] providing molecular evidence of ductal origin. Based on the above characteristics, it was believed that pancreatic clear cell carcinoma is a variation of pancreatic ductal adenocarcinoma.[@b5-ott-11-8197] HNF-1β may be a useful marker to identify these clear cell carcinomas, and its overexpression may aid in stratifying survival rate,[@b7-ott-11-8197] but in our case, HNF-1β was negative. Primary pancreatic clear cell carcinoma must be distinguished from the pancreatic neuroendocrine tumor, solid pseudopapillary tumor, mixed ductal-endocrine carcinoma, and pancreatic metastasis from clear cell renal cell carcinoma.[@b8-ott-11-8197] Of these, the most confusing tumor seems to be metastatic renal cell carcinoma.[@b9-ott-11-8197],[@b10-ott-11-8197] However, it is not very difficult to distinguish this tumor from it. History of renal tumors, preoperative CT, and MRI findings contribute to differential diagnosis. Postoperative immunohistochemistry of renal clear cell carcinoma showed positive reactions to antibodies against CD10, CA9, and Pax2, while immunonegative to CK-7.[@b11-ott-11-8197]--[@b13-ott-11-8197] Because it is a rare tumor with very few cases reported previously, the incidence and prognosis are not well known for this neoplasm. However, we found that most of the reported cases showed aggressive behavior portending poor outcome, especially when the tumor was located in the tail of the pancreas.

Conclusion
==========

We presented an extremely rare case of pancreatic clear cell ductal adenocarcinoma, which can be regarded as a rare variant of ductal adenocarcinoma in the proper morphology context supported by immunohistochemistry. Genetic analysis for detecting K-ras mutations and biomarker studies, such as HNF-1β, would aid in the identification of this rare neoplasm, but it is not absolute.

Written informed consent was acquired from the patient with approval of case detail and related patient information for publication use. Institutional approval was not required to publish this case report.
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![CT showed a 40 × 45 mm heterogeneous irregular hypodense mass in the distal body and tail of the pancreas (**A**), and it was enhanced after infusion of contrast material (**B**). PET-CT showed diffuse abnormal uptake only in the pancreatic mass (**C**).\
**Abbreviation:** PET-CT, positron emission tomography-computed tomography.](ott-11-8197Fig1){#f1-ott-11-8197}

![Gross photograph showing a firm and grayish white tumor from the spleen and the rest of the pancreas (**A**). Microscopically, it was predominantly composed of cells with abundant clear cytoplasm and well-defined cell borders (**B**, **C**).\
**Note:** Black arrow points to a typical clear neoplastic cell.](ott-11-8197Fig2){#f2-ott-11-8197}

![Immunohistochemically, tumor cells showed positivity for CK-7 (**A**) and negative for HNF-1β (**B**) and CA9 (**C**).\
**Abbreviations:** CA9, carbonic anhydrase 9; CK-7, cytokeratin-7; HNF-1β, hepatocyte nuclear factor-1β.](ott-11-8197Fig3){#f3-ott-11-8197}

###### 

The previously reported cases of primary clear cell adenocarcinoma of the pancreas

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                   Year   Age/sex       Location in pancreas                Morphology                                                                  Immunohistochemical profile
  ------------------------ ------ ------------- ----------------------------------- --------------------------------------------------------------------------- --------------------------------------------------------------------------------------------
                                                                                                                                                                

  Present case             2018   64 M          Body and tail metastatic to liver   Abundant clear cytoplasm and prominent cell                                 Positive: CK-7\
                                                                                                                                                                Negative: HNF-1β, CA9, SYN, CGA

  Modi Y et al             2013   75 F          Body and tail metastatic to liver   Highly atypical glands with abundant clear cells with well define borders   Positive: vimentin, CK-7, MUC, PAS, PASD, CEA, CA19--9\
                                                                                                                                                                Negative: AFP, CK-20, CGA, SYN, Hep Par-1, HMB-45, and GPC3

  Lee et al                2009   66 F          Tail, metastatic to liver           Nests of clear cells with rhabdoid features                                 Positive: P-CK, CK-7, CEA, EMA\
                                                                                                                                                                Negative: CK-20, CGA, SYN, SMA, and HMB-45

  Jamali et al             2007   75 M          Uncinate process                    Vacuolated cytoplasm and raisinoid nuclei with rhabdoid components          Positive: CK, Vimentin\
                                                                                                                                                                Negative: unspecified

  Ray et al                2005   46 M          Head, metastatic to omentum         Pleomorphic and hyperchromatic nuclei with abundant clear cytoplasm         Positive: CK-7, CEA\
                                                                                                                                                                Negative: PSA, TG, HMB-45, SYN, CGA

  Batoroev and Nguyen      2004   60 M          Head and body                       Vacuolated cytoplasm and pleomorphic nuclei with conspicuous nucleoli       Positive: PAS, PASD, mucicarmine, CEA\
                                                                                                                                                                Negative: vimentin

  Sasaki et al             2004   61 F          Body                                Clear cell nests with scanty fibrous stroma                                 Positive: CK-8, CK-19, CA-199, AAT\
                                                                                                                                                                Negative: CEA, NSE, CGA, SYN, insulin, glucagon, somatostatin, gastrin, trypsin, and HMB45

  Ray et al                2004   75 M          Tail                                Pleomorphic cells with abundant clear cytoplasm (\>95% clear cells)         Positive: CK-7, CAM 5.2, CK20, CEA, NSE\
                                                                                                                                                                Negative: SYN, CGA, vimentin, p53, HMB-45, CD10, PASD, AAT

  Luttges et al            1998   53 M          Head                                Primarily intraductal with solid invasive clear cell component              Positive: CK-7, CK-8, CK-18, CK-19, PASD, CEA, p53, AAT\
                                                                                                                                                                Negative: vimentin, CGA, SYN

  Taziaux et al            1994   70 M          Head, extension into duodenum       Cords and nests in highly vascular stroma                                   Positive: KL-1 (epithelial), vimentin\
                                                                                                                                                                Negative: CGA, PSA

  Kanai et al              1987   71 M          Body and tail, widely metastatic    Solid, trabecular, and nested                                               Positive: PAS, alcian blue\
                                                                                                                                                                Negative: sudan III

  Urbanski and Medline     1982   57 M          Body, widely metastatic             Multiple clear cells interspersed throughout the spindle and giant cells    Positive: alcian green, PAS, PASD\
                                                                                                                                                                Negative: oil red

  Cubilla and Fitzgerald   1980   Unspecified   Unspecified                         Unspecified                                                                 Positive: mucin\
                                                                                                                                                                Negative: unspecified
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** AAT, α-1-antitrypsin; AFP, alpha-fetoprotein; CA9, carbonic anhydrase 9; CA19--9, carbohydrate antigen 19--9; CEA, carcinoembryonic antigen; CGA, chromogranin A; CK, cytokeratin; EMA, epithelial membrane antigen; GPC3, glypican-3; Hep Par-1, hepatocyte paraffin-1; HMB-45, human melanoma black-45; HNF-1β, hepatocyte nuclear factor-1β ; MUC, mucicarmine; PAS, periodic acid-Schiff; PASD, periodic acid-Schiff with diastase; PSA, prostate-specific antigen; SMA, smooth muscle actin; SYN, synaptophysin; TG, thyroglobulin.
